Physician profile
Fady G Kadifa
NPI 1083711014
$3,854.94
in general payments reported to CMS, 2019-2025
30 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $307 · 2021: $1,525 · 2022: $987 · 2023: $83.05 · 2024: $82.23 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322 · Education: $28.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.74 |
| Education | $28.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,200.00 | 2021 | |
| Verathon INC. | $500.00 | 2022 | |
| Glaxosmithkline, LLC. | $485.87 | 2019-2024 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.02 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Inari Medical, INC. | $205.66 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Stryker Corporation | $129.19 | 2025 | Flowtriever |
| Astrazeneca Pharmaceuticals LP | $105.70 | 2019-2022 | |
| Genzyme Corporation | $74.17 | 2022-2024 | |
| Grifols USA, LLC | $73.48 | 2019-2021 | |
| Insmed, INC. | $72.45 | 2020-2023 | Arikayce |
| Janssen Pharmaceuticals, INC | $63.53 | 2020-2022 | |
| Mylan Specialty L.P. | $58.56 | 2019-2022 | |
| Pulmonx Corporation | $57.84 | 2021 | |
| Vifor Pharma, INC. | $47.74 | 2024-2025 | Zemaira |
| Regeneron Healthcare Solutions, INC. | $35.71 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $32.09 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $31.18 | 2019 | |
| Philips North America LLC | $29.81 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.07 | 2022 | |
| Resmed Corp | $28.87 | 2025 | |
| Portola Pharmaceuticals, LLC | $27.62 | 2019 | |
| Advanced Respiratory, INC | $23.31 | 2021 | |
| Genentech USA, INC. | $21.60 | 2019 | |
| Allergan, INC. | $20.00 | 2020 | |
| Ambu INC. | $18.86 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.63 | 2019 | |
| Merck Sharp & Dohme LLC | $18.42 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.88 | 2022 | |
| Circassia INC. | $17.21 | 2019 | |
| Shire North American Group INC | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Kadifa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.